Sun Pharma Welcomes Jeremy Allen as New VP of Corporate Affairs for North America

Sun Pharma Welcomes Jeremy Allen as New VP of Corporate Affairs

On October 22, 2025, Sun Pharmaceutical Industries Limited made a significant announcement regarding a key appointment in its North American operations. The company declared that Jeremy Allen has stepped into the role of Vice President of Corporate Affairs for the region. This newly established position will position him at the forefront of Sun Pharma's interactions with governmental entities, public policy, advocacy, and communications across the United States and Canada.

Richard Ascroft, the CEO of Sun Pharma North America, expressed his enthusiasm about Jeremy's appointment: "We are thrilled to welcome Jeremy to Sun Pharma. With his expertise and strategic vision, he will play a crucial role in driving the growth of our business. His leadership will be instrumental in enhancing our stakeholder engagement, shaping policy initiatives, and ensuring that our voice resonates strongly with those who depend on our innovative medicines, generics, and consumer healthcare products."

In his new role, Jeremy Allen will be responsible for directing Sun Pharma's external communications and policy initiatives, as well as overseeing patient advocacy and government relations. With more than 25 years of experience in the healthcare sector, he brings a wealth of knowledge in leading policy campaigns and initiatives that align with the company's mission.

Before joining Sun Pharma, Jeremy served as the leader of U.S. government affairs and pricing reimbursement functions at Spark Therapeutics. His extensive background also includes leading the federal lobbying team at AHIP (America's Health Insurance Plans) and holding government affairs roles at Vertex Pharmaceuticals and Johnson & Johnson. Notably, he began his career in public service, working on Capitol Hill and at the Centers for Disease Control and Prevention (CDC).

Jeremy shared his thoughts on this opportunity by stating: "I’m honored to join Sun Pharma at such a pivotal time in its growth journey. As the company continues to expand its footprint across U.S. and Canada, I look forward to shaping and sharing the story of Sun Pharma's commitment to enhancing patient lives through accessible, high-quality medicines. With innovative medicines addressing unmet patient needs and generics that are crucial in reducing healthcare costs, my role will be vital in strengthening trust and ensuring we meet the needs of the patient communities we serve."

Sun Pharmaceutical Industries has established itself as the world's leading specialty generics company, boasting a comprehensive range of products in innovative medicines, generics, and consumer healthcare. It is celebrated for its high growth in innovative medicines, particularly in dermatology, ophthalmology, and onco-dermatology, which generates approximately 20% of the company's total sales. With manufacturing operations spanning six continents, Sun Pharma ensures the delivery of high-quality medicines regarded highly by physicians and consumers across over 100 countries.

As Jeremy takes on this strategic leadership role, the industry will be watching to see how he influences the company's trajectory amidst ongoing innovations and market dynamics in healthcare.

For more updates and further details about Sun Pharma, visit their website or connect with them on LinkedIn.